GlassScriptPhysician profile
Ravneet Bajwa
NPI 1396033700
$4,894.88
in general payments reported to CMS, 2019-2025
52 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $23.86 · 2021: $173 · 2022: $915 · 2023: $1,265 · 2024: $1,344 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,274.00 |
| Education | $190.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $360.35 | 2019-2025 | |
| Intuitive Surgical, INC. | $253.61 | 2023-2025 | Da Vinci Surgical System |
| Amgen INC. | $230.87 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Janssen Biotech, INC. | $225.59 | 2023-2025 | Darzalex, Tecvayli, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $222.34 | 2021-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Seagen INC. | $215.15 | 2020-2023 | Tukysa, Padcev, Adcetris |
| Boston Scientific Corporation | $207.69 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $189.38 | 2019-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $180.12 | 2021-2025 | Xtandi, Vyloy |
| Celgene Corporation | $174.99 | 2022-2025 | Pomalyst, Opdivo, Reblozyl |
| Eisai INC. | $166.97 | 2023-2025 | |
| Steris Corporation | $153.17 | 2024 | |
| Lilly USA, LLC | $152.81 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Merck Sharp & Dohme LLC | $137.98 | 2019-2025 | Keytruda |
| Gilead Sciences, INC. | $136.24 | 2022-2025 | Trodelvy |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $133.94 | 2019-2025 | Venclexta, Tecentriq, Phesgo |
| Pfizer INC. | $132.18 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $121.27 | 2019-2024 | Imfinzi, Enhertu, Calquence |
| Galvanize Therapeutics, INC | $116.52 | 2024 | Aliya System |
| Abbvie INC. | $105.71 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $105.35 | 2019 | |
| Glaxosmithkline, LLC. | $103.80 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Daiichi Sankyo INC. | $95.27 | 2021-2024 | Enhertu, Injectafer |
| Adaptive Biotechnologies Corporation | $92.53 | 2022-2024 | Clonoseq |
| Exelixis INC. | $70.72 | 2019-2025 | Cabometyx |
| Pharmaessentia USA Corporation | $67.75 | 2023-2024 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $54.25 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $48.50 | 2019-2023 | |
| Aveo Pharmaceuticals, INC. | $46.73 | 2025 | |
| Alexion Pharmaceuticals, INC. | $42.98 | 2022-2024 | Ultomiris |
| Incyte Corporation | $42.66 | 2023-2024 | Jakafi, Pemazyre |
| Genzyme Corporation | $41.59 | 2022-2023 | |
| Sobi, INC | $38.65 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $38.34 | 2022 | |
| Springworks Therapeutics, INC. | $36.65 | 2024-2025 | Ogsiveo |
| Pharmacyclics LLC, An Abbvie Company | $34.68 | 2019-2023 | Imbruvica |
| Foundation Medicine, INC. | $32.02 | 2022-2023 | |
| Taiho Oncology, INC. | $25.93 | 2025 | |
| Deciphera Pharmaceuticals INC. | $23.51 | 2024 | Qinlock |
| Caris Mpi, INC. | $22.94 | 2025 | Mi Cancer Seek |
| Ipsen Biopharmaceuticals, INC | $22.75 | 2023 | Tazverik |
| Beigene USA, INC. | $22.02 | 2024 | Brukinsa |
| Stemline Therapeutics INC. | $21.19 | 2023 | Orserdu |
| Tempus Ai, INC | $20.90 | 2024 | Xt Cdx |
| Puma Biotechnology, INC. | $18.01 | 2024 | |
| Array Biopharma INC | $17.24 | 2025 | Mektovi, Braftovi, Lorbrena |
| Servier Pharmaceuticals LLC | $16.10 | 2024 | |
| G1 Therapeutics, INC. | $15.47 | 2023 | Cosela |
| Regeneron Healthcare Solutions, INC. | $15.29 | 2023 | Libtayo |
| Karyopharm Therapeutics INC. | $15.23 | 2023 | Xpovio |
| Blueprint Medicines Corporation | $14.63 | 2022 | |
| Novocure INC. | $14.32 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravneet Bajwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.